149 results
8-K
AGRX
Agile Therapeutics Inc
21 May 24
Entry into a Material Definitive Agreement
8:30am
materials (the “Secured Obligations”), Agile granted Corium a lien in the Company’s inventory up to the value of the Secured Obligations (“Secured Lien
8-K
AGRX
Agile Therapeutics Inc
25 Mar 24
Agile Therapeutics Announces Delisting from Nasdaq
4:30pm
$2,500,000 (the “Rule”). On June 2, 2023, based on the Staff’s review of the materials submitted by the Company, the Staff granted the Company’s request
8-K
EX-10.1
be2x2 7dw
23 Feb 24
Agile Therapeutics Announces Exercise of Warrants for $4.8 Million Gross Proceeds
4:30pm
8-K
hhntrxhdkzcf d443
15 Feb 24
Net Revenue for Full Year 2023 Expected to be in the Range of $20 to $21 Million, an Increase of 84% to 93% Compared to Full Year 2022
4:45pm
8-K
4o7ftae0aiadh
6 Dec 23
Other Events
8:00am
8-K
EX-10.1
dewfvdfnvjs8y903wo0
4 Dec 23
Entry into a Material Definitive Agreement
8:00am
8-K
61e8uw a74
2 Oct 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:30pm
8-K
EX-10.1
iieg5aa
28 Sep 23
Entry into a Material Definitive Agreement
4:50pm
S-8
EX-99.1
wrhl9w 41s2yfuxwr
9 Jun 23
Registration of securities for employees
5:19pm
8-K
EX-10.1
cnauijl
25 May 23
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
5:25pm